EGFR Mutasyonu Olan bir Hastada K���k H�creli Akci�er Kanserine D�n���m Yoluyla Geli�en Epidermal B�y�me Fakt�r� Resept�r�-Tirozin Kinaz �nhibit�r Direnci

K�z�lg�z, Derya; Kabalak, P�nar Ak�n; Cengiz, Tuba Inal; Y�lmaz, �lk�; �zayd�n, Hatice Esra; Ekinci, �zg�r; Aky�rek, Nalan; Kavurgac�, Suna

Cilt : 13 Say� : 3 Y�l : 2024

13/3Son Say� Erken Bask� Ar�iv Pop�ler Makaleler

Yay�n Hakk� Devir Formu

Yazar Katk� Formu

H�zl� Arama

EGFR Mutasyonu Olan bir Hastada K��k H�creli Akci�er Kanserine D�n��m Yoluyla Geli�en Epidermal B�y�me Fakt�r� Resept�r�-Tirozin Kinaz �nhibit�r Direnci [Respir Case Rep]

Respir Case Rep. 2017; 6(3): 161-165 | DOI: 10.5505/respircase.2017.48403

EGFR Mutasyonu Olan bir Hastada K��k H�creli Akci�er Kanserine D�n��m Yoluyla Geli�en Epidermal B�y�me Fakt�r� Resept�r�-Tirozin Kinaz �nhibit�r Direnci

Derya K�z�lg�z¹, P�nar Ak�n Kabalak¹, Tuba Inal Cengiz¹, �lk� Y�lmaz¹, Hatice Esra �zayd�n², �zg�r Ekinci³, Nalan Aky�rek³, Suna Kavurgac�¹
¹Ankara Atat�rk G��s Hastal�klar� ve G��s Cerrahisi E�itim Ara�t�rma Hastanesi,G��s Hastal�klar� Anabilim Dal�,Ankara,T�rkiye
²Atat�rk G��s Hastal�klar� ve G��s Cerrahisi E�itim Ara�t�rma Hastanesi,Patoloji Anabilim Dal�,Ankara,T�rkiye
³Gazi �niversitesi T�p Fak�ltesi, Patoloji Anabilim Dal� Ankara, T�rkiye

K��k h�cre d�� akci�er karsinomunda subtiplendirmenin yap�lmas� �nemlidir. Epidermal growth factor resept�r (EGFR) Egzon 19 delesyonuna sahip adenokarsinomlu olgularda, gefitinib ve erlotinib olarak bilinen EGFR-Tirozin kinaz inhibit�r� tedaviler ile ileri evre hastalarda sa�kal�mda fayda elde edilebilmektedir. Ancak bir�ok molek�ler ve biyolojik mekanizmalar ile bu ila�lara kar�� diren� geli�ebilmektedir. Bu yaz�da, erlotinib tedavisinin 13. ay�nda, diren� mekanizmalar�ndan biri olan k��k h�creli akci�er kanseri d�n��m�n�, bir olgu e�li�inde sunmay� ama�lad�k.

Anahtar Kelimeler: K��k H�cre D�� Akci�er Kanseri, Epidermal B�y�me Fakt�r� Tirozin Kinaz �nhibit�rleri, Rezistans Mekanizmalar�, K��k H�creli Akci�er Kanseri D�n��m�

Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors by Transformation to Small Cell Lung Cancer in an EGFR-mutant Patient

Derya K�z�lg�z¹, P�nar Ak�n Kabalak¹, Tuba Inal Cengiz¹, �lk� Y�lmaz¹, Hatice Esra �zayd�n², �zg�r Ekinci³, Nalan Aky�rek³, Suna Kavurgac�¹
¹Department of Chest Disease, Ankara Atat�rk Chest Disease and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
²Department of Pathology, Ankara Atat�rk Chest Disease and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
³Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey

It is important to determine the histological tumor type in non-small cell lung cancer (NSCLC). In patients with adenocarcinoma harboring the epidermal growth factor receptor (EGFR) exon 19 deletion mutation, targeted therapy can yield survival benefit. The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib can provide survival benefit for advanced stage NSCLC patients. However, increasing evidence of acquired resistance to these drugs has been reported, and numerous molecular and biological mechanisms of acquired resistance have been detected. The present report is description of 1, such resistance mechanisms: transformation to small cell lung cancer in a patient who was in the 13th month of erlotinib therapy.

Keywords: Non-small cell lung cancer, epidermal growth factor tyrosine kinase inhibitors, resistance mechanism, small cell carcinoma transformation

Sorumlu Yazar: Derya K�z�lg�z, T�rkiye
Makale Dili: �ngilizce

ATIF KOPYALA

Tam Metin PDF At�f dosyas� indir RIS EndNote BibTex Medlars Procite Reference Manager Yazara e-posta g�nder Benzer makaleler PubMed Google Scholar

H�zl� Arama

EGFR Mutasyonu Olan bir Hastada K���k H�creli Akci�er Kanserine D�n���m Yoluyla Geli�en Epidermal B�y�me Fakt�r� Resept�r�-Tirozin Kinaz �nhibit�r Direnci

Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors by Transformation to Small Cell Lung Cancer in an EGFR-mutant Patient

EGFR Mutasyonu Olan bir Hastada K��k H�creli Akci�er Kanserine D�n��m Yoluyla Geli�en Epidermal B�y�me Fakt�r� Resept�r�-Tirozin Kinaz �nhibit�r Direnci